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Oxidatively modified low-density-lipoprotein (LDL) might contribute to the atherosclerotic process. This study was performed to examine an effect 
of platelet-activating factor (PAF) and of synthetic PAF analogs on Cu(II) induced oxidation of LDL in vitro: The D- and L-isomers of PAF and 
analogs with short-chain sn-2-substituents, l-O-alkyl-2-butyryl-sn-glycero-3-phosphocholine a d I-O-alkyl-2-heptanoyl-sn-glycero-3-phospho- 
choline, were found to be the most effective inhibitors of LDL oxidation. Oxidation was inhibited completely at PAF concentrations above 100 
PM. Lyso-PAF and analogs carrying longer chains at the sn-2 position were less effective. These results thus provide evidence for the involvement 
of other parameters in LDL oxidation beyond the content of natural antioxidants like vitamin E and /?-carotene. 
Platelet-activating factor: Low-density lipoprotein; Oxidation; Phospholipid 
1. INTRODUCTION 
Evidence is now accumulating for a critical role of 
oxidized lipoproteins in the pathophysiology of athero- 
sclerosis [l-3]. Several studies have found a correlation 
between the lipid peroxides in the circulating plaque and 
arteriosclerosis [4]; oxidized low-density lipoprotein 
(ox-LDL) has been demonstrated in atherosclerotic pla- 
ques from human and the Watanabe rabbit [5-71. Ox- 
LDL potentially has several modes of action in athero- 
genesis. First, in particular macrophagocytic foam cells 
of the atheromatous lesion very intensively exhibit im- 
munocytochemical staining for ox-LDL epitopes [5]. 
Macrophages avidly take up ox-LDL isolated from the 
atherosclerotic lesion by scavenger eceptors and form 
cytoplasmic cholesteryl ester-rich lipid droplets in the 
cytoplasma, but do not metabolize native plasma LDL 
at increased rates. Uptake of ox-LDL by macrophages 
induces their conversion to cholesteryl ester-rich ‘foam 
cells’ [8]. Second, ox-LDL might perpetuate plaque 
growth by enhancing monocyte recruitment and macro- 
phage retention in the atherosclerotic lesions: it exhibits 
chemoattractive activity for monocytes and migration 
inhibitory activity for macrophages [9-l 11. Third, ox- 
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LDL is cytotoxic at low concentrations and is antigenic; 
these potentials of ox-LDL could cause endothelial cell 
death, formation of thrombi, and further enhance the 
rate of progression from the early lesions to the fibrous 
plaque stage and the formation of thrombi [12]. 
At this point, the mechanisms underlying the LDL 
oxidation in vivo are not well understood. Several in 
vitro model systems for studying oxidation of LDL 
were established. LDL can be oxidized by cultured 
monocytes/macrophages [13-l 51, endothelial cells 
[16,17], smooth muscle cells [18], by treatment with 
lipoxygenase and phospholipase A, [19-211, and incu- 
bation with redox metals [17,22]. It is believed that the 
oxidation of the polyunsaturated fatty acids of the LDL 
particles in these systems generate aldehydic thiobar- 
bituric acid-reactive substances which might modify the 
positively charged amino-acid residues of apolipopro- 
tein B. Lipophilic and hydrophilic antioxidants uch as 
vitamin E [23], vitamin C, uric acid [22] and redox metal 
chelators protect LDL in these in vitro systems and 
indicate a causative role of reactive oxygen species in the 
LDL ‘modification process. Preventive antioxidant 
treatment with probucol was shown to reduce the rate 
of LDL degradation in the arterial wall in Watanabe 
rabbits and to dramatically prevent the formation and 
progression of atheromatous lesions in their aortas 
[24-271. 
The extent of modification of LDL in vitro by reac- 
tive oxygen species could be diminished to some extent 
when HDL were added to the in vitro LDL oxidation 
assay [28]. The protective effect of HDL is potentially 
very interesting, since an inverse correlation of HDL 
and premature atherosclerosis was observed. However, 
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the mechanism by which HDL protects LDL is puzzling 
and could not be clarified in detail. It was found that 
only the rate of ox-LDL degradation by macrophages 
but not the formation of TBARS in the LDL oxidation 
assay was altered by HDL. Several possibilities were 
discussed. It was proposed that the protection of LDL 
from oxidative modification by HDL might be related 
to a rapid exchange of oxidized phospholipids from 
LDL with unoxidized HDL phospholipids, or a compe- 
tition between LDL and HDL phospholipids for oxida- 
tion, or trapping of reactive lipophilic aldehydes in the 
lipid phase of HDL [28]. In addition, a phospholipase 
AZ in the apolipoprotein B of the LDL [20] and/or the 
platelet-activating factor acetylhydrolase associated 
with LDL and HDL [29-3 l] could further modulate the 
modification of oxidizing LDL by lipid-peroxidation 
endproducts and modify LDL metabolism by macro- 
phages. 
When we decided to test for a possible effect of l-O- 
hexadecyl-2-acetyl-s-glycero-3-phosphocholine, the 
platelet-activating factor (PAF), we had speculations 
for a biological role of PAF in LDL oxidation. Lyso- 
PAF is produced in activated leukocytes by a phospho- 
lipase A2 at considerable quantities from 1 -hexadecyl-2- 
arachidonyl-PC and then converted to PAF which accu- 
mulates in subcellular membranes up to rather high 
concentrations (0.5 mol%), possibly high enough to in- 
fluence vesicle fusion and biological properties of the 
membranes [32]. On the other hand, plasma contains 
PAF acetylhydrolase, 60-70% of its activity associated 
with LDL and 3&40% with HDL, which abolishes the 
biological activity of PAF by hydrolysis of the acetyl 
residue [29,30,33]. Therefore only low concentrations of 
this unusual phospholipid are found in plasma lipopro- 
teins. Does PAF and its acetylhydrolase influence LDL 
oxidation? In the atherosclerotic lesion epitopes of ox- 
LDL were predominantly localized intracellularly in 
foam cells, where high concentrations of PAF might 
occur [5]. PAF might move from subcellular membranes 
to LDL and influence the rate of its modification. 
We decided to test for a possible effect of PAF 
micelles on LDL oxidation by the addition of PAF to 
the LDL oxidation assay, in the presence of Cu(I1) ions 
and in an assay system with linoleic acid. The effect of 
PAF on LDL stability was quantified in the presence of 
HDL to study the influence of HDL and a role of the 
HDL-associated PAF acetylhydrolase. Another aim of 
the study was then to consider the ranking of active 
analogues of PAF according to their activity in the 
Cu(I1) ion-dependent LDL oxidation assay and to com- 
pare this effect with the LDL-stabilizing activity of the 
known LDL-protective antioxidant, probucol. 
2. MATERIALS AND METHODS 
2.1. Materials 
Chemicals were purchased from E. Merck (Darmstadt, Germany), 
Sigma (Munich, Germany), and Aldrich Chemical Co. (Steinheim, 
Germany). Biochemicals were purchased from Boehringer Mannheim 
GmbH (Mannheim, Germany). 
2.2. Synthesis of phospholipids 
I-Palmitoyl-2-acetyl-phosphocholine- and I-0-palmityl-2-sn-glyc- 
ero-3-phosphocholine analogues containing butyryl and heptanoyl 
groups at the sn-2 position were prepared from lyso-PAF and lyso- 
lecithin and the appropriate acid anhydride by the method of Gupta 
et al. [34]. l-0-octadecyl-2-O-methyl-phosphatidylcholine (rat.) was 
generously provided by Dr. A. Hermetter (University of Graz, Aus- 
tria). The products were purified by silica gel chromatography using 
chloroform/methanoYH,0, 55:40:3 as solvent system. The concentra- 
tion of the products was determined by TLC as described by Colarow 
[35]. Phospholipids in 20 mM Tris-HCl, pH 8.4, 150 mM NaCl (TN 
buffer) were sonicated for 15 s prior to use. 
Table I 
Substituent effects on LDL oxidation” 
a 
b- 
phosphocholine 
Compound 
a 
Substituent Duration of the Slope of the curve during 
lag phase the propagation phase 
b (% of control)b (8 of control)b 
L-PAF 
D-PAF 
Lyso-PAF 
I-0-hexadecyl 
1 -O-hexadecyl 
I-0-hexadecyl 
I-0-hexadecyl 
1 -O-hexadecyl 
1-0-palmitoyl 
1-0-stearoyl 
I-0-octadecyl 
2-acetyl 157 71 
2-acetyl 143 72 
-OH 106 98 
2-butyryl (rat) 167 68 
2-heptanoyl (rat) 163 63 
2-oleoyl 108 93 
2-lauroyl 109 92 
2-O-methyl (rat) 142 67 
“Conditions for LDL oxidation as described in the legend to Fig. 1. 
bConcentration of test compound was 50 ,uM. 
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2.3. Isolation of LDL and LDL oxidation with Cu(lI) ions as prooxi- 
dant 
Human plasma was obtained from healthy volunteers. EDTA (pH 
7.4) was added to prevent blood clotting. LDL was isolated from 
pooled plasma by sequential flotation in an ultracentrifuge at prese- 
lected densities as described [36]. The concentration of LDL protein 
was determined with the BCA protein assay reagent (Pierce Chemical 
Co., Rockford, IL, USA) and bovine albumin as standard [37]. LDL 
was kept sterile under nitrogen at 4°C in 20 mM Tris-HCl, pH 8, 150 
mM NaCl, 0.1 mM EDTA (TN buffer) up to two weeks and dialyzed 
against TN buffer prior to use. 
LDL was oxidized at a concentration of 125 pg/ml(O.25 PM) in the 
presence of 10 PM copper(I1) as prooxidant in TN buffer. Aliquots 
of 2 ml were analyzed at 42°C from 0 to 400 min. The oxidation 
reaction was followed at 234 nm as described by Esterbauer et al. [38] 
and the appearance of dienes at A,,, was recorded. The so-called ‘lag 
phase’ (defined as the interval between the intercept of the tangent of 
the slope of the curve with the time-scale axis), and the maximal rate 
of AZ)., formation (calculated from the slope of the absorbance curve 
during the propagation reaction) was estimated. 
2.4. Oxidation of linolerc acid m presence of Cu(lI) 
Linoleic acid was dispersed into TN buffer. Oxidation assays con- 
tained linoleic acid at a concentration of 1 mM, 100 PM Cu(I1) with 
and without D-PAF at a concentration of 50 PM. The samples were 
then incubated at 42°C. The rate of oxidation was monitored by the 
Increase of the conjugated iene level at 234 nm. 
3. RESULTS 
in our assay (Table I). Some of the analogues clearly 
exhibit inhibitory activity on LDL oxidation at a con- 
centration of 50 ,uM. L-PAF, D-PAF, compounds 4, 5 
and 8 prolong the lag phase by 42-67%, and reduce the 
rate of the increase of the dienes during the propagation 
reactions by about 30%. The inhibitory effects are de- 
pendent on the concentration of the 1-O-alkyl-2-acetyl- 
sn-glycero-3-phosphocholines in the assays as shown 
for L-PAF over a concentration range of 25-160 PM in 
Fig. 1. The inhibitory activity of L-PAF, D-PAF, com- 
pounds 4 and 5, appears to be rather insensitive to the 
variation of chain length at the sn-2 position and also 
compound 8 exhibited good inhibitory activity; how- 
ever, the substitutions with longer alkyl chains such as 
oleoyl and lauroyl residues had only little inhibitory 
activity at a concentration of 50 PM. When compared 
with the effect of phenolic antioxidants like probucol on 
a molar basis, the LDL-stabilizing activity of the L- 
PAF, D-PAF, compounds 4, 5 and 8 appears rather 
weak. As published by us before [40], probucol pro- 
longed at a much lower concentration of 2.5 ,uM the lag 
phase of the oxidizing LDL by about 60%, however, 
unlike the sn-glycero-3-phosphocholines, the phenolic 
antioxidant did not influence the rate of the propaga- 
tion reaction. 
3.1. Characteristics of the LDL oxidation reaction 3.3. Effect of PAF and PAF analogues on LDL oxida- 
Incubation for oxidation of 0.25 ,uM LDL (125 ,ugl 
ml) in Tris-HCl buffer at pH 8 with Cu(I1) at 42°C 
results in a slight increase of A,,, during the lag phase 
and a rapid increase during the propagation phase be- 
fore reaching a maximal value. When we analyzed 20 
LDL samples from various healthy donors under our 
conditions we obtained values of A,,, between 0.28 and 
0.41/0.25 ,uM LDL protein at the beginning of the incu- 
bation and a mean increase of 0.05 O.D. units during 
the ‘lag phase’, which lasted 62-95 min (77 f. 8, 
mean k SD.); the maximal increases during the ‘propa- 
gation reaction’ were 0.240.3 O.D. units/l0 min and 
the maximal values reached at the end of the propaga- 
tion phases were 0.85-1.08 O.D. units. Assuming a 
molar extinction coefficient eM = 2.4 x 104/mol . cm for 
diene absorption the level of conjugated dienes was cal- 
culated to increase by 70 dienes per LDL during the lag 
phase and by -900 dienes per LDL particle during the 
propagation phase. 
tion in presence of HDL 
We conducted experiments using 2 HDL particles per 
LDL particle (0.5 ,uM HDL and 0.25 ,uM LDL) and 50 
,uM PAF and PAF analogues. The results clearly show 
that concomittantly with HDL the prolongation of the 
lag phase of oxidizing LDL caused by PAF and PAF 
analogues in the Cu(I1) assay is shortened and that the 
LDL is less effectively stabilized by PAF and its tested 
analogues (data not shown). 
3.4. Effect of PAF on the oxidation of linoleic acid (LA) 
Micelles containing 1 mM LA appeared to be unsta- 
ble in the oxidation assay containing 100 PM Cu(I1) and 
A 234 
3.2. Effect of PAF and PAF analogues on the LDL oxi- 
+ 
+ 
+ 
dation reaction 
LDL 
20 uM PAF 
50 uMPAF 
100 pMPAF 
Stremler et al. have hypothesized that oxidation and 
fragmentation of phospholipids containing polyunsatu- 
rated fatty acid acyl residues hould generate phosphol- 
ipids with varying m-2 residues and that PAF acetylhy- 
drolase is sensitive to the length of the sn-2 residue [39]. 
Stimulated by their findings, we tested eight sn-glycero- 
3-phosphocholines, derivatives of platelet activating 
factor l-0alkyl-2-acetyl-sn-glycero-3-phosphocholine 
0,3’ 
0 60 120 180 240 300 360 
Time (min.) 
Fig. 1. Kinetics of the LDL oxidation m presence of Cu(I1) and PAF 
as determined by formation of dienes (A,,,). 0.25 PM LDL in 20 mM 
Tris-HCl, pH 8, 150 mM NaCl, 10 PM CuCIZ and 0,20 PM, 50 PM, 
100 PM L-PAF was incubated at 42°C. 
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were oxidized over an incubation period of 5 h as indi- 
cated by a continuous increase of dienes at ATj4. After 
a 6-h incubation period the A234 values reached a pla- 
teau. Addition of 50 PM PAF to the oxidation medium 
did not protect the linoleic acid from oxidation. In the 
presence of 50 ,uM PAF even a slight left shift of the 
diene curve was seen (Fig. 2). This phenomenon indi- 
cates a slightly faster oxidation in presence of PAF. 
4. DISCUSSION 
Incubations of LDL with l-0alkyl-2-acetyl-sn-glyc- 
ero-3-phosphocholine (platelet activating factor), and 
its m-2 substituents l-O-alkyl-2-butyryl-sn-glycero-3- 
phosphocholine and 1-O-alkyl-2-heptanoyl-sn-glycero- 
3-phosphocholine protected LDL, since they caused a 
prolonged stability of the LDL particles against reactive 
oxygen generated in presence of copper(I1) ions. The D- 
and the L-isomers of platelet activating factor (PAF) 
exhibited a nearly equal effect on the lag phase of the 
diene curve. Lyso-PAF appeared to be less active than 
D- and L-PAF during the lag phase of the diene curve, 
however, it also decreased the rate of the hydrogen 
abstraction and diene formation during the propagation 
phase. The butyryl- and the heptanoyl substituents at 
the sn-2 position of PAF caused a slightly less prolonga- 
tion of the lag phase when compared with D- and L- 
PAF, however, they both, like PAF, had only little ef- 
fect on the propagation rate. PAF m-2 long acyl chain 
substituents did neither significantly influence the lag 
period nor the propagation reaction of the oxidizing 
LDL particle. Exchange of the ester for an ether bond 
at the sn-1 position had no effect on the kinetics of LDL 
oxidation. Addition of HDL diminished the LDL pro- 
tective effect of PAF and its analogues. PAF had no 
antioxidant effect and was not protecting linoleic acid 
against oxidation. 
The reactions occurring in oxidizing LDL particles 
are very complex and not well understood. Therefore 
many possibilities remain. A few out of a long list could 
be addressed by our pilot studies. First, the antioxidant 
A 234 
Control 
+ PAF (50 PM) 
0,4- 
0 2 4 6 
Time (h) 
Fig. 2. Effect of 50 ,uM L-PAF on the Cu(II) initiated oxidation of 
1 mM linoleic acid. Incubation was as described in the legend 
to Fig. 1. 
content of LDL, and in particular the concentration of 
vitamin E as the predominant lipophilic phenolic anti- 
oxidant of LDL, are critical for LDL stability. We have 
no evidence that PAF has antioxidant activity even at 
rather high concentrations in the assay with linoleic acid 
and LDL. In these two assays the numbers of PUFAs 
are comparable. Antioxidants like probucol and B- 
estradiol are highly effectively inhibiting LDL oxidation 
at concentrations ~1 yM [40]. However, the LDL anti- 
oxidants are not the only factor stabilizing LDL and 
there are reports of only a weak correlation and even 
a lack of correlation between the content of antioxi- 
dants and the duration of the lag phase of oxidizing 
LDL particles [41]. A second possibility is repair of 
LDL by PAF during the lag phase increasing stability 
of LDL in presence of copper(I1) ions. It was shown 
recently that LDL particles, after reducing the hydro- 
peroxide tone of the particle by combined treatment 
with glutathione peroxidase ebselen and glutathione, 
become highly resistant in presence of copper(I1) ions. 
It was concluded that hydroperoxides carried by the 
LDL particles are necessary to generate Cu(I), an initi- 
ator of the Fenton reaction, and therefore are most 
important determinants of the duration of the lag phase 
[42]. Our data show that PAF reduces the hydroperox- 
ide tone in LDL, since it delays formation of dienes, but 
we have no evidence for an active repair process. Third, 
PAF micelles could trap intermediate products released 
by oxidizing LDL and indirectly prolong the lag phase 
of LDL. HDL was suggested to protect LDL particles 
via an exchange of phospholipid hydroperoxides [28]. 
Parthasarathy et al. hypothesized that phospholipids 
from LDL might exchange phospholipids with unoxi- 
dized HDL. PAF micelles could act via an exchange of 
phospholipid hydroperoxides in our LDL oxidation 
assay; our results confirm that HDL was without effect 
on the formation of lipid peroxides as observed [28]. In 
the presence of PAF we observed no additive effect of 
HDL on the formation of dienes in the assay. Paradox- 
ically HDL even reduced protection of LDL by PAF in 
the LDL oxidation assay. Thus, other mechanisms 
should be responsible for LDL stabilization by PAF. 
Fourth, the LDL-associated PAF acetyl hydrolase 
could influence the lag phase of the LDL in the Cu(I1) 
assay. Stremler et al. [31] synthesized and tested the 
effect of various PAF m-2 analogues and their effect on 
the purified enzyme. When they increased and extended 
the length of the sn-2 residue to 9 carbon atoms the 
catalytic effect of purified PAF acetylhydrolase was re- 
duced dramatically [31]. Our results demonstrate that 
the prolongation of the lag phase in our LDL oxidation 
assay caused by the presence of PAF and analogues was 
also maximal with PAF and its short-chain sn-2 ana- 
logues and decreased when the m-2 chain length was 
extended and substitution of the sn-2 position with a 
short chain ether had a comparable LDL stabilizing 
activity showing that also an ether bond has compara- 
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ble activity. This analogy makes it possible that PAF 
acetylhydrolase content of LDL is a critical determinant 
for the duration of the lag phase of LDL. If this is true, 
the observed influence of HDL on the PAF-induced 
prolongation of the LDL lag phase could be explained 
by the HDL associated PAF acetylhydrolase, which 
could reduce PAF concentration in the assay. 
Thus, our experiments demonstrate that PAF and its 
sn-2 short chain analogues prolong the lag phase of 
LDL in presence of Cu(II). This effect of the test com- 
pounds could be caused by competitive inhibition of the 
LDL-associated PAF acetylhydrolase. These observa- 
tions shed light on a role for the PAF acetylhydrolase 
in LDL oxidation. The concentration and activity of 
PAF acetylhydrolase could be a determinant of the du- 
ration of the lag phase and cause variability in the sta- 
bility of LDL particles. Further analyses in our labora- 
tories are on the way to test for the extent of variation 
in LDL stability caused by PAF acetylhydrolase associ- 
ated with LDL from healthy people and patients with 
altered lipoprotein metabolism. 
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